|
Preliminary findings from part 1 of COMBI-i: A phase III study of anti–PD-1 antibody PDR001 combined with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600-mutant melanoma. |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche; Takeda |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche; Takeda |
Research Funding - Amgen; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche; Takeda |
|
Ana María Arance Fernández |
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; Novartis; Roche/Genentech |
|
|
Honoraria - Bristol-Myers Squibb; Eisai; GlaxoSmithKline; MSD; Novartis; Pfizer; Roche |
Research Funding - Bristol-Myers Squibb; MSD; Novartis; Pfizer |
|
|
Honoraria - Bristol-Myers Squibb; Incyte; Merck; Novartis; Roche |
Consulting or Advisory Role - Amgen; Array BioPharma; Bristol-Myers Squibb; Incyte; MERCK; Novartis; Pierre Fabre; Roche/Genentech |
|
|
|
Stock and Other Ownership Interests - Amgen; Novartis |
|
|
|
Stock and Other Ownership Interests - Novartis |
|
|
|
Stock and Other Ownership Interests - Novartis |
Travel, Accommodations, Expenses - Novartis |
|
|
Employment - GlaxoSmithKline; Novartis |
Stock and Other Ownership Interests - AstraZeneca; GlaxoSmithKline; Incyte; Novartis |
|
|
Honoraria - Bristol-Myers Squibb; MSD; Novartis |
Consulting or Advisory Role - Bristol-Myers Squibb; Merck Serono; MSD; Novartis; Pierre Fabre |
Speakers' Bureau - Bristol-Myers Squibb; MSD; Novartis; Roche |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD |